XML 106 R75.htm IDEA: XBRL DOCUMENT v3.21.1
Collaborative and Other Relationships - Equity Method Investments (Details)
$ in Millions, ₩ in Billions
1 Months Ended 3 Months Ended
Nov. 30, 2018
USD ($)
Nov. 30, 2018
KRW (₩)
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Mar. 31, 2021
KRW (₩)
Dec. 31, 2020
USD ($)
Dec. 31, 2020
KRW (₩)
Jan. 31, 2020
USD ($)
Nov. 07, 2018
USD ($)
Schedule of Equity Method Investments [Line Items]                      
Our share of Samsung Bioepis gains (losses)     $ 18.2 $ 16.8              
Collaboration profit (loss) sharing     68.5 71.8              
Total revenue     $ 2,694.0 $ 3,534.3              
Samsung Bioepis                      
Schedule of Equity Method Investments [Line Items]                      
Percentage of stake in entity       5.00%              
Percentage of stake in entity maximum     49.90%       49.90%        
Payments to acquire additional investment in equity method investment $ 676.6 ₩ 759.5       $ 676.6          
Amortization of basis differences                     $ 675.0
Loss recorded on Samsung Bioepis joint venture     $ 18.2 $ 14.8              
Investment in Samsung Bioepis     $ 576.3       ₩ 653.4 $ 620.2 ₩ 673.8    
Biogen share of co-promotion profits or losses     50.00%                
Collaboration profit (loss) sharing     $ 68.5 71.8              
Eisai                      
Schedule of Equity Method Investments [Line Items]                      
Loss on research and development contracts terminated with Eisai         $ 45.0            
Our share of Samsung Bioepis gains (losses)     (33.8)                
Additional Milestone Payment     75.0                
Samsung Bioepis                      
Schedule of Equity Method Investments [Line Items]                      
Upfront and milestone payments made to collaborative partner       100.0              
Research and development expense       63.0              
Prepaid research and development expenses                   $ 37.0  
Estimated additional payments upon achievement of development and commercial milestones     195.0                
Additional Milestone Payment     15.0                
Contract Option Exercise Fee       $ 60.0              
Due to Related Parties     $ 188.4         $ 99.0      
Inventory | Samsung Bioepis                      
Schedule of Equity Method Investments [Line Items]                      
Equity method investment basis difference amortization period     1 year 6 months                
Developed technology | Samsung Bioepis                      
Schedule of Equity Method Investments [Line Items]                      
Equity method investment basis difference amortization period     15 years